Ghana

Ghana

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
9.07 (8.28 - 9.92) 2019 Modelled IHME
9.08 (8.32 - 9.78) 2018 Modelled IHME
9.11 (8.32 - 9.92) 2017 Modelled IHME
9.68 (8.87 - 10.41) 2016 Modelled IHME
10.47 (9.55 - 11.30) 2015 Modelled IHME
10.9 (9.98 - 11.72) 2014 Modelled IHME
11.25 (10.26 - 12.09) 2013 Modelled IHME
11.56 (10.54 - 12.46) 2012 Modelled IHME
11.86 (10.78 - 12.87) 2011 Modelled IHME
12.19 (11.06 - 13.29) 2010 Modelled IHME
12.56 (11.43 - 13.64) 2009 Modelled IHME
12.94 (11.82 - 14.01) 2008 Modelled IHME
13.33 (12.20 - 14.40) 2007 Modelled IHME
13.72 (12.53 - 14.87) 2006 Modelled IHME
14.09 (12.87 - 15.29) 2005 Modelled IHME
14.49 (13.26 - 15.69) 2004 Modelled IHME
14.92 (13.62 - 16.12) 2003 Modelled IHME
15.33 (14.03 - 16.56) 2002 Modelled IHME
15.67 (14.31 - 16.99) 2001 Modelled IHME
15.9 (14.52 - 17.28) 2000 Modelled IHME
16.04 (14.74 - 17.43) 1999 Modelled IHME
16.15 (14.89 - 17.51) 1998 Modelled IHME
16.23 (14.96 - 17.59) 1997 Modelled IHME
16.32 (15.07 - 17.72) 1996 Modelled IHME
16.42 (15.12 - 17.87) 1995 Modelled IHME
16.54 (15.27 - 17.98) 1994 Modelled IHME
16.66 (15.41 - 18.06) 1993 Modelled IHME
16.79 (15.53 - 18.16) 1992 Modelled IHME
16.92 (15.62 - 18.31) 1991 Modelled IHME
17.06 (15.73 - 18.50) 1990 Modelled IHME
8.63 (7.19 - 10.34) 2015 Modelled WHO
12.92 (12.44 - 13.42) 2013 Modelled Schweitzer et al, 2015
12.3 (11.30 - 13.40) 2015 Modelled Ofori-Asenso and Agyeman, 2016
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.64 (0.50 - 0.80) 2019 Modelled IHME
0.66 (0.52 - 0.81) 2018 Modelled IHME
0.71 (0.55 - 0.87) 2017 Modelled IHME
0.94 (0.75 - 1.15) 2016 Modelled IHME
1.25 (1 - 1.55) 2015 Modelled IHME
1.45 (1.18 - 1.79) 2014 Modelled IHME
1.64 (1.35 - 2.01) 2013 Modelled IHME
1.8 (1.49 - 2.21) 2012 Modelled IHME
1.94 (1.60 - 2.39) 2011 Modelled IHME
2.06 (1.69 - 2.53) 2010 Modelled IHME
2.14 (1.77 - 2.59) 2009 Modelled IHME
2.2 (1.82 - 2.64) 2008 Modelled IHME
2.25 (1.86 - 2.70) 2007 Modelled IHME
2.33 (1.92 - 2.80) 2006 Modelled IHME
2.45 (1.99 - 2.96) 2005 Modelled IHME
3.46 (2.86 - 4.19) 2004 Modelled IHME
5.68 (4.71 - 6.86) 2003 Modelled IHME
8.32 (6.88 - 10.02) 2002 Modelled IHME
10.59 (8.70 - 12.80) 2001 Modelled IHME
11.7 (9.57 - 14.22) 2000 Modelled IHME
11.93 (9.72 - 14.40) 1999 Modelled IHME
12.09 (9.88 - 14.55) 1998 Modelled IHME
12.21 (9.92 - 14.55) 1997 Modelled IHME
12.31 (9.93 - 14.65) 1996 Modelled IHME
12.42 (9.99 - 14.79) 1995 Modelled IHME
12.55 (10.16 - 15.01) 1994 Modelled IHME
12.68 (10.34 - 15.09) 1993 Modelled IHME
12.81 (10.50 - 15.20) 1992 Modelled IHME
12.93 (10.65 - 15.26) 1991 Modelled IHME
13.05 (10.80 - 15.37) 1990 Modelled IHME
3.61 (2.50 - 5) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
51 (42 - 60) 2019 Modelled IHME
51 (42 - 60) 2018 Modelled IHME
51 (42 - 60) 2017 Modelled IHME
51 (42 - 60) 2016 Modelled IHME
51 (42 - 59) 2015 Modelled IHME
51 (42 - 60) 2014 Modelled IHME
51 (43 - 60) 2013 Modelled IHME
52 (43 - 61) 2012 Modelled IHME
52 (44 - 61) 2011 Modelled IHME
52 (44 - 61) 2010 Modelled IHME
52 (44 - 61) 2009 Modelled IHME
52 (44 - 61) 2008 Modelled IHME
52 (44 - 61) 2007 Modelled IHME
52 (44 - 61) 2006 Modelled IHME
52 (44 - 61) 2005 Modelled IHME
52 (44 - 61) 2004 Modelled IHME
53 (44 - 61) 2003 Modelled IHME
53 (45 - 61) 2002 Modelled IHME
54 (45 - 62) 2001 Modelled IHME
54 (45 - 62) 2000 Modelled IHME
54 (45 - 62) 1999 Modelled IHME
54 (45 - 62) 1998 Modelled IHME
54 (45 - 62) 1997 Modelled IHME
53 (45 - 62) 1996 Modelled IHME
53 (44 - 62) 1995 Modelled IHME
53 (44 - 62) 1994 Modelled IHME
53 (44 - 62) 1993 Modelled IHME
53 (44 - 62) 1992 Modelled IHME
53 (44 - 62) 1991 Modelled IHME
53 (44 - 62) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
97 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
93 2016 Survey/reported WHO/UNICEF
88 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
90 2013 Survey/reported WHO/UNICEF
92 2012 Survey/reported WHO/UNICEF
91 2011 Survey/reported WHO/UNICEF
94 2010 Survey/reported WHO/UNICEF
94 2009 Survey/reported WHO/UNICEF
93 2008 Survey/reported WHO/UNICEF
94 2007 Survey/reported WHO/UNICEF
84 2006 Survey/reported WHO/UNICEF
84 2005 Survey/reported WHO/UNICEF
80 2004 Survey/reported WHO/UNICEF
80 2003 Survey/reported WHO/UNICEF
80 2002 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HBV testing policy
Risk-based
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
None
% of substance use disorder facilities offering hepatitis treatment
None

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
3.33 (2.65 - 4.20) 2019 Modelled IHME
3.33 (2.67 - 4.20) 2018 Modelled IHME
3.34 (2.67 - 4.22) 2017 Modelled IHME
3.35 (2.69 - 4.20) 2016 Modelled IHME
3.36 (2.69 - 4.20) 2015 Modelled IHME
3.38 (2.70 - 4.22) 2014 Modelled IHME
3.42 (2.73 - 4.28) 2013 Modelled IHME
3.47 (2.78 - 4.34) 2012 Modelled IHME
3.52 (2.83 - 4.40) 2011 Modelled IHME
3.56 (2.87 - 4.48) 2010 Modelled IHME
3.6 (2.91 - 4.49) 2009 Modelled IHME
3.64 (2.94 - 4.53) 2008 Modelled IHME
3.68 (2.99 - 4.57) 2007 Modelled IHME
3.73 (3.02 - 4.57) 2006 Modelled IHME
3.79 (3.04 - 4.62) 2005 Modelled IHME
3.87 (3.14 - 4.68) 2004 Modelled IHME
3.97 (3.27 - 4.74) 2003 Modelled IHME
4.09 (3.39 - 4.84) 2002 Modelled IHME
4.19 (3.50 - 4.95) 2001 Modelled IHME
4.27 (3.56 - 5.04) 2000 Modelled IHME
4.32 (3.60 - 5.11) 1999 Modelled IHME
4.38 (3.63 - 5.18) 1998 Modelled IHME
4.43 (3.66 - 5.24) 1997 Modelled IHME
4.46 (3.67 - 5.31) 1996 Modelled IHME
4.47 (3.67 - 5.33) 1995 Modelled IHME
4.47 (3.68 - 5.31) 1994 Modelled IHME
4.47 (3.66 - 5.30) 1993 Modelled IHME
4.46 (3.64 - 5.33) 1992 Modelled IHME
4.44 (3.61 - 5.32) 1991 Modelled IHME
4.42 (3.57 - 5.34) 1990 Modelled IHME
1.4 (1.10 - 3.40) 2015 Modelled Blach et al, 2017
1.5 (0.90 - 4.10) 2015 Modelled Maaroufi et al, 2017
1.4 (1.10 - 3.40) 2017 Modelled Sonderup et al, 2017
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
3.2 (0.50 - 8.10) 2014 Modelled Riou et al, 2015
2 (1.20 - 5.50) 2014 Modelled Maaroufi et al, 2017
3 (2.60 - 3.50) 2015 Modelled Agyeman et al, 2016
3.2 (0.50 - 8.10) 2017 Modelled Sonderup et al, 2017
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
40.1 (34.80 - 45.40) 2005 Survey/reported Adjei A et al, 2007

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
14 (9 - 19) 2019 Modelled IHME
14 (9 - 19) 2018 Modelled IHME
14 (9 - 19) 2017 Modelled IHME
14 (9 - 19) 2016 Modelled IHME
14 (10 - 19) 2015 Modelled IHME
14 (10 - 19) 2014 Modelled IHME
14 (10 - 19) 2013 Modelled IHME
14 (10 - 19) 2012 Modelled IHME
14 (10 - 19) 2011 Modelled IHME
14 (10 - 20) 2010 Modelled IHME
14 (10 - 20) 2009 Modelled IHME
14 (10 - 20) 2008 Modelled IHME
14 (10 - 20) 2007 Modelled IHME
14 (10 - 20) 2006 Modelled IHME
14 (10 - 20) 2005 Modelled IHME
14 (10 - 20) 2004 Modelled IHME
14 (10 - 19) 2003 Modelled IHME
14 (10 - 19) 2002 Modelled IHME
14 (9 - 19) 2001 Modelled IHME
14 (10 - 19) 2000 Modelled IHME
14 (10 - 19) 1999 Modelled IHME
14 (10 - 19) 1998 Modelled IHME
14 (10 - 20) 1997 Modelled IHME
15 (10 - 20) 1996 Modelled IHME
15 (10 - 20) 1995 Modelled IHME
15 (10 - 20) 1994 Modelled IHME
15 (10 - 20) 1993 Modelled IHME
15 (10 - 20) 1992 Modelled IHME
15 (10 - 20) 1991 Modelled IHME
15 (10 - 21) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HBV testing policy
Risk-based
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
None
% of substance use disorder facilities offering hepatitis treatment
None

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
9.07 (%)
2019
(8.28 - 9.92(%))
IHME
HCV (RNA/cAg+)
3.33 (%)
2019
(2.65 - 4.2(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
3,118
2019
(2,273 - 4,155)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
552
2019
(387 - 764)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.64 (%)
2019, latest modelled
(0.50 - 0.80(%))
IHME

Prevalence PWID

HCV
0
, latest modelled

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines